BIO-TECHNE Corp
BIO-TECHNE Corp
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Financial statements beyond 3 years are for subscribers only. Unlock 17+ years of income statements, balance sheets, and cash flow statements Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||||||||||
Assets Current | |||||||||||||||||
Cash And Cash Equivalents At Carrying Value | 265 | 210 | 173 | 145 | 162 | 141 | 178 | 188 | 152 | 140 | 130 | 149 | |||||
Short Term Investments | - | - | - | - | - | 0 | 0 | - | 1 | 5 | 6 | - | |||||
Accounts Receivable Net Current | 217 | 215 | 185 | 184 | 207 | 237 | 218 | 224 | 241 | 228 | 207 | 205 | |||||
Inventory Net | 196 | 201 | 205 | 203 | 189 | 191 | 188 | 185 | 180 | 179 | 181 | 186 | |||||
Assets Of Disposal Group Including Discontinued Op… | - | - | - | - | 12 | 5 | 1 | 9 | 10 | 27 | 27 | - | |||||
Other Assets Current | 67 | 62 | 74 | 77 | 37 | 54 | 50 | 43 | 34 | 31 | 40 | 52 | |||||
Assets Current | 744 | 688 | 637 | 610 | 608 | 627 | 635 | 649 | 617 | 611 | 591 | 591 | |||||
Property Plant And Equipment Net | 232 | 233 | 234 | 240 | 246 | 252 | 250 | 254 | 251 | 244 | 234 | 232 | |||||
Operating Lease Right Of Use Asset | 67 | 68 | 68 | 71 | 73 | 84 | 85 | 89 | 91 | 97 | 101 | 102 | |||||
Goodwill | 975 | 978 | 981 | 979 | 981 | 969 | 965 | 983 | 973 | 971 | 980 | 969 | |||||
Intangible Assets Net Excluding Goodwill | 303 | 319 | 335 | 350 | 366 | 444 | 461 | 486 | 507 | 526 | 551 | 579 | |||||
Deferred Income Tax Assets Net | - | - | - | - | 10 | - | - | - | - | - | - | - | |||||
Other Assets Noncurrent | 264 | 264 | 267 | 277 | 284 | 269 | 275 | 276 | 264 | 272 | 274 | 282 | |||||
Assets | 2,587 | 2,551 | 2,523 | 2,526 | 2,558 | 2,644 | 2,670 | 2,736 | 2,704 | 2,721 | 2,731 | 2,755 | |||||
Liabilities And Stockhold… | |||||||||||||||||
Liabilities Current | |||||||||||||||||
Accounts Payable Current | 27 | 23 | 26 | 30 | 25 | 32 | 33 | 32 | 38 | 29 | 32 | 28 | |||||
Employee Related Liabilities Current | 58 | 54 | 45 | 44 | 66 | 62 | 54 | 42 | 50 | 44 | 33 | 35 | |||||
Accrued Liabilities Current | 20 | 18 | 20 | 19 | 26 | 24 | 28 | 21 | 25 | 18 | 17 | 16 | |||||
Contract With Customer Liability Current | 36 | 38 | 31 | 30 | 33 | 32 | 28 | 27 | 28 | 30 | 28 | 25 | |||||
Accrued Income Taxes Current | 4 | 3 | 2 | 3 | 11 | 4 | 3 | 3 | 4 | 12 | 7 | 6 | |||||
Operating Lease Liability Current | 15 | 14 | 14 | 14 | 14 | 14 | 14 | 13 | 13 | 13 | 13 | 12 | |||||
Business Combination Contingent Consideration Liab… | - | - | - | - | - | - | - | - | - | 0 | - | 2 | |||||
Liabilities Of Disposal Group Including Discontinu… | - | - | - | - | - | - | - | - | - | 1 | 2 | - | |||||
Other Liabilities Current | 4 | 2 | 2 | 5 | 2 | 2 | 3 | 4 | 2 | 3 | 4 | 4 | |||||
Liabilities Current | 164 | 153 | 140 | 145 | 176 | 169 | 161 | 142 | 159 | 150 | 135 | 128 | |||||
Deferred Income Tax Liabilities Net | 19 | 14 | 11 | 11 | 6 | 32 | 38 | 50 | 56 | 64 | 72 | 83 | |||||
Long Term Debt And Capital Lease Obligations | 200 | 200 | 260 | 300 | 346 | 330 | 300 | 300 | 319 | 389 | 447 | 440 | |||||
Operating Lease Liability Noncurrent | 74 | 76 | 77 | 81 | 84 | 79 | 82 | 85 | 88 | 93 | 96 | 97 | |||||
Other Liabilities Noncurrent | 21 | 22 | 23 | 24 | 27 | 16 | 11 | 20 | 13 | 12 | 17 | 9 | |||||
Equity | |||||||||||||||||
Common Stock Value | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | |||||
Additional Paid In Capital Common Stock | 1,033 | 1,005 | 965 | 946 | 911 | 902 | 876 | 856 | 820 | 790 | 764 | 747 | |||||
Retained Earnings Accumulated Deficit | 1,144 | 1,145 | 1,107 | 1,083 | 1,066 | 1,196 | 1,287 | 1,341 | 1,325 | 1,298 | 1,261 | 1,328 | |||||
Accumulated Other Comprehensive Income Loss Net Of… | -71 | -67 | -62 | -64 | -60 | -82 | -86 | -60 | -78 | -75 | -64 | -78 | |||||
Stockholders Equity | - | 2,085 | 2,011 | 1,966 | 1,919 | 2,018 | 2,078 | 2,139 | 2,069 | 2,014 | 1,964 | 1,998 | |||||
Liabilities And Stockholders Equity | 2,587 | 2,551 | 2,523 | 2,526 | 2,558 | 2,644 | 2,670 | 2,736 | 2,704 | 2,721 | 2,731 | 2,755 | |||||
Allowance For Doubtful Accounts Receivable Current | 5 | 4 | 4 | 4 | 4 | 6 | 6 | 5 | 4 | 3 | 4 | 5 | |||||
Common Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |||||
Common Stock Shares Authorized | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | |||||
Common Stock Shares Issued | 156 | 157 | 156 | 156 | 155 | 157 | 158 | 159 | 158 | 158 | 157 | 158 | |||||
Shares Outstanding | 156 | 157 | 156 | 156 | 155 | 157 | 158 | 159 | 158 | 158 | 157 | 158 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 7.77% | -1.07% | 13.87% | -13.97% | -25.70% | -20.98% | 9.21% | 50.03% | 51.30% | - | - | - |
| 2025 | -2.81% | -5.88% | -0.63% | -17.58% | -21.61% | -32.94% | -2.61% | 4.31% | 18.27% | -10.21% | 2.75% | 0.56% |
| 2024 | 8.45% | 29.60% | 21.99% | 12.22% | 6.20% | -3.35% | 1.59% | -5.70% | 6.08% | 4.65% | 2.82% | 6.57% |
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.
Metrics | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Metric history beyond 3 years is for subscribers only. Unlock 17+ years of history across 90+ calculated metrics Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Liquidity Ratios | |||||||||||||||||
| Current Ratio | 4.55 | 4.49 | 4.54 | 4.22 | 3.46 | 3.71 | 3.94 | 4.56 | 3.87 | 4.08 | 4.37 | 4.63 | |||||
| Quick Ratio | 3.35 | 3.18 | 3.08 | 2.81 | 2.38 | 2.58 | 2.77 | 3.26 | 2.75 | 2.88 | 3.03 | 3.17 | |||||
| Working Capital | 580.70M | 534.77M | 497.01M | 464.96M | 432.45M | 458.04M | 473.38M | 506.44M | 458.04M | 460.83M | 455.41M | 463.72M | |||||
Leverage & Debt | |||||||||||||||||
| Debt to Equity | 0.07 | 0.07 | 0.07 | 0.07 | 0.09 | 0.08 | 0.08 | 0.07 | 0.08 | 0.07 | 0.07 | 0.06 | |||||
| Debt Ratio | 0.06 | 0.06 | 0.06 | 0.06 | 0.07 | 0.06 | 0.06 | 0.05 | 0.06 | 0.06 | 0.05 | 0.05 | |||||
Efficiency & Turnover | |||||||||||||||||
| Asset Turnover TTM | 0.47 | 0.47 | 0.47 | 0.46 | 0.46 | 0.45 | 0.44 | 0.43 | 0.43 | 0.43 | 0.45 | 0.45 | |||||
| Days Sales Outstanding TTM | 63.60 | 68.08 | 60.44 | 61.13 | 67.08 | 70.21 | 64.91 | 66.71 | 72.41 | 70.25 | 62.51 | 60.42 | |||||
| Receivables Turnover TTM | 5.74 | 5.36 | 6.04 | 5.97 | 5.44 | 5.20 | 5.62 | 5.47 | 5.04 | 5.20 | 5.84 | 6.04 | |||||
Per Share Metrics | |||||||||||||||||
| Diluted EPS TTM | 1.16 | 0.70 | 0.52 | 0.50 | 0.46 | 0.83 | 0.98 | 0.94 | 1.05 | 1.26 | 1.40 | 1.52 | |||||
| Free Cash Flow Per Share TTM | 1.69 | 1.72 | 1.43 | 1.44 | 1.63 | 1.40 | 1.61 | 1.55 | 1.50 | 1.60 | 1.43 | 1.36 | |||||
| Dividend Per Share TTM | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | |||||
Margin Metrics | |||||||||||||||||
| Gross Profit Margin TTM | 65.77% | 64.96% | 65.22% | 65.37% | 64.80% | 65.75% | 65.62% | 65.51% | 66.41% | 66.80% | 67.13% | 67.78% | |||||
| Operating Profit Margin TTM | 20.73% | 12.70% | 9.62% | 9.03% | 8.38% | 14.22% | 16.74% | 16.29% | 17.83% | 22.13% | 23.46% | 26.09% | |||||
| Net Profit Margin TTM | 14.97% | 9.05% | 6.67% | 6.41% | 6.02% | 10.89% | 13.22% | 12.86% | 14.50% | 17.57% | 19.56% | 21.55% | |||||
Growth Metrics | |||||||||||||||||
| Net Revenue Growth (1Y) | -0.38% | 0.17% | 1.64% | 3.85% | 5.23% | 4.72% | 4.46% | 2.41% | 1.97% | 2.73% | 2.25% | 2.37% | |||||
| Net Income Growth (1Y) | 147.77% | -16.79% | -48.71% | -48.26% | -56.34% | -35.08% | -29.40% | -38.86% | -41.07% | -25.46% | -14.72% | -15.81% | |||||
| EPS Growth (1Y) | 150.24% | -16.23% | -47.86% | -47.23% | -56.28% | -35.11% | -29.80% | -39.02% | -41.27% | -25.46% | -15.00% | -16.45% | |||||
Valuation Metrics | |||||||||||||||||
| P/E TTM | 60.52 | 74.35 | 112.52 | 110.27 | 109.63 | 69.46 | 71.45 | 83.16 | 66.41 | 53.88 | 53.50 | 42.99 | |||||
| P/B TTM | 4.54 | 3.91 | 4.54 | 4.37 | 4.19 | 4.53 | 5.44 | 5.86 | 5.40 | 5.43 | 6.10 | 5.30 | |||||
| P/S TTM | 9.06 | 6.73 | 7.51 | 7.07 | 6.60 | 7.57 | 9.45 | 10.70 | 9.63 | 9.47 | 10.47 | 9.26 | |||||
| Market Cap | 11.01B | 8.15B | 9.13B | 8.60B | 8.05B | 9.15B | 11.30B | 12.53B | 11.16B | 10.93B | 11.98B | 10.60B | |||||
| Enterprise Value | 10.94B | 8.14B | 9.21B | 8.75B | 8.23B | 9.34B | 11.42B | 12.65B | 11.33B | 11.18B | 12.30B | 10.89B | |||||
Calculated Values | |||||||||||||||||
| Free Cash Flow TTM | 263.22M | 269.60M | 223.02M | 224.06M | 256.55M | 220.76M | 254.30M | 245.03M | 236.10M | 251.15M | 225.39M | 215.42M | |||||
| Net Debt | -64.71M | -9.82M | 87.12M | 155.04M | 183.81M | 189.33M | 122.45M | 112.46M | 167.21M | 249.09M | 316.87M | 291.34M | |||||
Per-Share and Margin | |||||||||||||||||
| EPS TTM | |||||||||||||||||
| Adjusted EPS TTM | |||||||||||||||||
| Cash Flow Per Share TTM | |||||||||||||||||
| Pretax Margin TTM | |||||||||||||||||
| Stock Comp to Revenue TTM | |||||||||||||||||
Turnover Ratios and Averages | |||||||||||||||||
| Average Assets | |||||||||||||||||
| Average Equity | |||||||||||||||||
| Average Inventory | |||||||||||||||||
| Average Receivables | |||||||||||||||||
| Average Accounts Payables | |||||||||||||||||
| Inventory Turnover TTM | |||||||||||||||||
| Payables Turnover TTM | |||||||||||||||||
| Days Inventory Outstanding TTM | |||||||||||||||||
| Days Payables Outstanding TTM | |||||||||||||||||
| Cash Conversion Cycle TTM | |||||||||||||||||
| Working Capital to Revenue | |||||||||||||||||
| Deferred Revenue to Revenue | |||||||||||||||||
Growth Rates | |||||||||||||||||
| Total Assets Growth (1Y) | |||||||||||||||||
| Total Assets Growth (3Y) | |||||||||||||||||
| Total Assets Growth (5Y) | |||||||||||||||||
| Dividends Paid Growth (1Y) | |||||||||||||||||
| Dividends Paid Growth (3Y) | |||||||||||||||||
| Dividends Paid Growth (5Y) | |||||||||||||||||
| EPS Growth (3Y) | |||||||||||||||||
| EPS Growth (5Y) | |||||||||||||||||
| Net Income Growth (3Y) | |||||||||||||||||
| Net Income Growth (5Y) | |||||||||||||||||
| Net Profit Margin Growth (1Y) | |||||||||||||||||
| Net Profit Margin Growth (3Y) | |||||||||||||||||
| Net Profit Margin Growth (5Y) | |||||||||||||||||
| Net Revenue Growth (3Y) | |||||||||||||||||
| Net Revenue Growth (5Y) | |||||||||||||||||
| Deferred Revenue Growth (1Y) | |||||||||||||||||
| Retained Earnings Growth (1Y) | |||||||||||||||||
Credit, Liquidity, Returns, Payout | |||||||||||||||||
| Cash Ratio | |||||||||||||||||
| Net Working Capital | |||||||||||||||||
| Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to Equity | |||||||||||||||||
| Altman A | |||||||||||||||||
| Altman B | |||||||||||||||||
| Altman C | |||||||||||||||||
| Altman D | |||||||||||||||||
| Altman E | |||||||||||||||||
| Altman Z-Score | |||||||||||||||||
| ROA TTM | |||||||||||||||||
| ROE TTM | |||||||||||||||||
| NOPAT TTM | |||||||||||||||||
| ROIC TTM | |||||||||||||||||
| Effective Tax Rate TTM | |||||||||||||||||
| Payout Ratio TTM | |||||||||||||||||
| Dilution Ratio | |||||||||||||||||
| Retained Earnings to Equity | |||||||||||||||||
| Treasury Stock to Equity | |||||||||||||||||
| Treasury Stock Change (1Y) | |||||||||||||||||
| Accrued to Current Liabilities | |||||||||||||||||
| NCAV | |||||||||||||||||
| NCAV Per Share TTM | |||||||||||||||||
Valuation Ratios | |||||||||||||||||
| P/CF TTM | |||||||||||||||||
| PEG Ratio | |||||||||||||||||
| Dividend Yield TTM | |||||||||||||||||
| Free Cash Flow Yield TTM | |||||||||||||||||
| EV EBITDA TTM | |||||||||||||||||
| EV EBIT TTM | |||||||||||||||||
| EV Revenue TTM | |||||||||||||||||
| EV FCF TTM | |||||||||||||||||
| Stock Compensation TTM | |||||||||||||||||
| Adjusted Net Income TTM | |||||||||||||||||
| Billings TTM | |||||||||||||||||
| Total Debt | |||||||||||||||||
| Invested Capital | |||||||||||||||||
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
BIO-TECHNE Corp (TECH) — SEC Financial Statements & Analysis
BIO-TECHNE Corp (TECH) is a biological products, (no diagnostic substances) company, incorporated in MN. BIO-TECHNE Corp trades on Nasdaq as: TECH. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), BIO-TECHNE Corp reported a -0.38% year-over-year revenue growth, a Gross Profit Margin of 65.77% (TTM), a Debt-to-Equity ratio of 0.07x, a Price-to-Sales (P/S) ratio of 9.06x (TTM), a Price-to-Book (P/B) ratio of 4.54x (TTM), at a market cap of $11.01B. Figures below are sourced from SEC EDGAR, as-filed.
- Net Revenue TTM Growth 1Y
- -0.38%
- Gross Profit Margin TTM
- 65.77%
- Debt To Equity
- 0.07x
- P/S TTM
- 9.06x
- P/B TTM
- 4.54x
- Market Cap
- $11.01B
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is BIO-TECHNE Corp in?
BIO-TECHNE Corp (TECH) operates in the Biological Products, (No Diagnostic Substances) industry.
What is TECH's market cap?
BIO-TECHNE Corp (TECH) has a market capitalization of $11.01B as of 2026-06-30.
What is TECH's P/E ratio?
BIO-TECHNE Corp (TECH)'s trailing twelve month P/E ratio is 60.52x as of 2026-06-30.
What exchange does TECH trade on?
BIO-TECHNE Corp (TECH) trades on the Nasdaq.
Where is BIO-TECHNE Corp incorporated?
BIO-TECHNE Corp is incorporated in MN.